{"id":48734,"date":"2022-09-23T12:02:06","date_gmt":"2022-09-23T10:02:06","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/alivamab-discovery-services-reappoints-dr-larry-green-as-chief-executive-officer\/"},"modified":"2022-09-23T12:02:06","modified_gmt":"2022-09-23T10:02:06","slug":"alivamab-discovery-services-reappoints-dr-larry-green-as-chief-executive-officer","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/alivamab-discovery-services-reappoints-dr-larry-green-as-chief-executive-officer\/","title":{"rendered":"AlivaMab Discovery Services Reappoints Dr. Larry Green as Chief Executive Officer"},"content":{"rendered":"
\n

SAN DIEGO–(BUSINESS WIRE)–AlivaMab Discovery Services (\u201cADS\u201d), a leader in the discovery of superior antibody-based therapeutics, announced that Larry Green has reassumed the role of Chief Executive Officer, effective immediately. He assumes the role from Justin Mika. Dr. Green, who brings over 30 years\u2019 experience in antibody drug discovery and development, is the founding Chief Executive Officer of ADS and has served as Executive Chair since May 2020. He continues in his role as CEO of Ablexis, LLC.\n<\/p>\n

<\/a><\/p>\n

\n\u201cWe thank Justin for his leadership in growing ADS during the past two years,\u201d said Dr. Green, Chief Executive Officer at AlivaMab Discovery Services. \u201cI look forward to continuing that growth, including new offerings in antibody drug discovery and engineering, and to working closely with our expanding roster of partners, leveraging the synergy of ADS\u2019 integrated fully human antibody drug discovery and engineering platforms with the ADS team\u2019s experience and know-how in antibody drug discovery.\u201d\n<\/p>\n

\n\u201cDr. Green has extensive experience in building and using antibody drug discovery systems, which was a key factor in Deerfield\u2019s investment in AlivaMab Discovery Services,\u201d said Cameron Wheeler, Partner at Deerfield Management and member of the Board of Directors of ADS. \u201cHe rejoins the ADS leadership team to help continue advancing the company\u2019s culture of partnership and innovation.\u201d\n<\/p>\n

\nAbout AlivaMab Discovery Services<\/b>\n<\/p>\n

\nAlivaMab Discovery Services (ADS) sets its partners\u2019 antibody discovery programs on the fastest and most de-risked path through discovery and development. Trusted by top-tier pharmaceutical and biotechnology companies, ADS delivers drug-quality, fully human antibodies on exceptional timelines. ADS rapidly and efficiently delivers truly molecularly diverse panels of antibodies, characterized for function, kinetics, and developability, plus antibody engineering for advanced modalities, including multispecifics and CARs. The ADS team\u2019s experience in antibody drug discovery and development comes from many of the world\u2019s top 15 pharmaceutical companies, including AbbVie, AstraZeneca, Bristol Myers Squibb, Novartis, Pfizer, and Roche\/Genentech, and translates across more than 500 discovery programs and 35 clinical candidates. This experience, combined with the use of trusted, proven technologies, including Ablexis\u2019 AlivaMab\u00ae Mouse platforms, ensures the highest probability of success. For more information, please visit www.alivamab.com<\/a> or email info@alivamab.com<\/a>.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nStacey Borders
\n
sborders@alivamab.com<\/a>
(858) 252-3420 x105\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

SAN DIEGO–(BUSINESS WIRE)–AlivaMab Discovery Services (\u201cADS\u201d), a leader in the discovery of superior antibody-based therapeutics, announced that Larry Green has reassumed the role of Chief Executive Officer, effective immediately. He assumes the role from Justin Mika. Dr. Green, who brings over 30 years\u2019 experience in antibody drug discovery and development, is the founding Chief Executive … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-48734","6":"format-standard","7":"category-industry"},"yoast_head":"\nAlivaMab Discovery Services Reappoints Dr. Larry Green as Chief Executive Officer - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/alivamab-discovery-services-reappoints-dr-larry-green-as-chief-executive-officer\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AlivaMab Discovery Services Reappoints Dr. Larry Green as Chief Executive Officer - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"SAN DIEGO–(BUSINESS WIRE)–AlivaMab Discovery Services (\u201cADS\u201d), a leader in the discovery of superior antibody-based therapeutics, announced that Larry Green has reassumed the role of Chief Executive Officer, effective immediately. He assumes the role from Justin Mika. Dr. Green, who brings over 30 years\u2019 experience in antibody drug discovery and development, is the founding Chief Executive ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/alivamab-discovery-services-reappoints-dr-larry-green-as-chief-executive-officer\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-09-23T10:02:06+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220923005122\/en\/1581033\/21\/AlivaMab-DS-logo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/alivamab-discovery-services-reappoints-dr-larry-green-as-chief-executive-officer\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/alivamab-discovery-services-reappoints-dr-larry-green-as-chief-executive-officer\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"AlivaMab Discovery Services Reappoints Dr. Larry Green as Chief Executive Officer\",\"datePublished\":\"2022-09-23T10:02:06+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/alivamab-discovery-services-reappoints-dr-larry-green-as-chief-executive-officer\\\/\"},\"wordCount\":376,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/alivamab-discovery-services-reappoints-dr-larry-green-as-chief-executive-officer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220923005122\\\/en\\\/1581033\\\/21\\\/AlivaMab-DS-logo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/alivamab-discovery-services-reappoints-dr-larry-green-as-chief-executive-officer\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/alivamab-discovery-services-reappoints-dr-larry-green-as-chief-executive-officer\\\/\",\"name\":\"AlivaMab Discovery Services Reappoints Dr. Larry Green as Chief Executive Officer - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/alivamab-discovery-services-reappoints-dr-larry-green-as-chief-executive-officer\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/alivamab-discovery-services-reappoints-dr-larry-green-as-chief-executive-officer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220923005122\\\/en\\\/1581033\\\/21\\\/AlivaMab-DS-logo.jpg\",\"datePublished\":\"2022-09-23T10:02:06+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/alivamab-discovery-services-reappoints-dr-larry-green-as-chief-executive-officer\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/alivamab-discovery-services-reappoints-dr-larry-green-as-chief-executive-officer\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/alivamab-discovery-services-reappoints-dr-larry-green-as-chief-executive-officer\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220923005122\\\/en\\\/1581033\\\/21\\\/AlivaMab-DS-logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220923005122\\\/en\\\/1581033\\\/21\\\/AlivaMab-DS-logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/alivamab-discovery-services-reappoints-dr-larry-green-as-chief-executive-officer\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"AlivaMab Discovery Services Reappoints Dr. Larry Green as Chief Executive Officer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"AlivaMab Discovery Services Reappoints Dr. Larry Green as Chief Executive Officer - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/alivamab-discovery-services-reappoints-dr-larry-green-as-chief-executive-officer\/","og_locale":"en_US","og_type":"article","og_title":"AlivaMab Discovery Services Reappoints Dr. Larry Green as Chief Executive Officer - Pharma Trend","og_description":"SAN DIEGO–(BUSINESS WIRE)–AlivaMab Discovery Services (\u201cADS\u201d), a leader in the discovery of superior antibody-based therapeutics, announced that Larry Green has reassumed the role of Chief Executive Officer, effective immediately. He assumes the role from Justin Mika. Dr. Green, who brings over 30 years\u2019 experience in antibody drug discovery and development, is the founding Chief Executive ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/alivamab-discovery-services-reappoints-dr-larry-green-as-chief-executive-officer\/","og_site_name":"Pharma Trend","article_published_time":"2022-09-23T10:02:06+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220923005122\/en\/1581033\/21\/AlivaMab-DS-logo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/alivamab-discovery-services-reappoints-dr-larry-green-as-chief-executive-officer\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/alivamab-discovery-services-reappoints-dr-larry-green-as-chief-executive-officer\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"AlivaMab Discovery Services Reappoints Dr. Larry Green as Chief Executive Officer","datePublished":"2022-09-23T10:02:06+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/alivamab-discovery-services-reappoints-dr-larry-green-as-chief-executive-officer\/"},"wordCount":376,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/alivamab-discovery-services-reappoints-dr-larry-green-as-chief-executive-officer\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220923005122\/en\/1581033\/21\/AlivaMab-DS-logo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/alivamab-discovery-services-reappoints-dr-larry-green-as-chief-executive-officer\/","url":"https:\/\/pharma-trend.com\/en\/alivamab-discovery-services-reappoints-dr-larry-green-as-chief-executive-officer\/","name":"AlivaMab Discovery Services Reappoints Dr. Larry Green as Chief Executive Officer - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/alivamab-discovery-services-reappoints-dr-larry-green-as-chief-executive-officer\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/alivamab-discovery-services-reappoints-dr-larry-green-as-chief-executive-officer\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220923005122\/en\/1581033\/21\/AlivaMab-DS-logo.jpg","datePublished":"2022-09-23T10:02:06+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/alivamab-discovery-services-reappoints-dr-larry-green-as-chief-executive-officer\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/alivamab-discovery-services-reappoints-dr-larry-green-as-chief-executive-officer\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/alivamab-discovery-services-reappoints-dr-larry-green-as-chief-executive-officer\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220923005122\/en\/1581033\/21\/AlivaMab-DS-logo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220923005122\/en\/1581033\/21\/AlivaMab-DS-logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/alivamab-discovery-services-reappoints-dr-larry-green-as-chief-executive-officer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"AlivaMab Discovery Services Reappoints Dr. Larry Green as Chief Executive Officer"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/48734","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=48734"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/48734\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=48734"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=48734"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=48734"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}